Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial

Myelofibrosis symptoms compromise health-related quality of life (HRQoL). Ruxolitinib can reduce myelofibrosis symptom severity, but many patients discontinue ruxolitinib due to loss of response or unacceptable toxicity. Fedratinib is an oral, selective JAK2 inhibitor approved in the United States f...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hemasphere
Main Authors: Harrison, Claire N., Schaap, Nicolaas, Vannucchi, Alessandro M., Kiladjian, Jean-Jacques, Jourdan, Eric, Silver, Richard T., Schouten, Harry C., Passamonti, Francesco, Zweegman, Sonja, Talpaz, Moshe, Verstovsek, Srdan, Tang, Derek, Abraham, Pranav, Lord-Bessen, Jennifer, Rose, Shelonitda, Guo, Shien, Liao, Weiqin, Mesa, Ruben A.
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8096470/
https://ncbi.nlm.nih.gov/pubmed/33969275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000562
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados